Literature DB >> 28043792

Generation of a novel artificial TrkB agonist, BM17d99, using T7 phage-displayed random peptide libraries.

Toshiyuki Ohnishi1, Kotaro Sakamoto2, Asano Asami-Odaka1, Kimie Nakamura1, Ayako Shimizu1, Takashi Ito1, Taiji Asami1, Tetsuya Ohtaki1, Hiroshi Inooka1.   

Abstract

Tropomyosin receptor kinase B (TrkB) is a known receptor of brain-derived neurotrophic factor (BDNF). Because it plays a critical role in the regulation of neuronal development, maturation, survival, etc., TrkB is a good target for drugs against central nervous system diseases. In this study, we aimed to generate peptidic TrkB agonists by applying random peptide phage display technology. After the phage panning against recombinant Fc-fused TrkB (TrkB-Fc), agonistic phages were directly screened against TrkB-expressing HEK293 cells. Through subsequent screening of the first-hit BM17 peptide-derived focus library, we successfully obtained the BM17d99 peptide, which had no sequence similarity with BDNF but had TrkB-binding capacity. We then synthesized a dimeric BM17d99 analog peptide that could phosphorylate or activate TrkB by facilitating receptor homodimerization. Treatment of TrkB-expressing HEK293 cells with the dimeric BM17d99 analog peptide significantly induced the phosphorylation of TrkB, suggesting that homodimerization of TrkB was enhanced by the dimeric peptide. This report demonstrates that our approach is useful for the generation of artificial peptidic agonists of cell surface receptors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Agonist; BDNF; Peptide; Phage display; TrkB

Mesh:

Substances:

Year:  2016        PMID: 28043792     DOI: 10.1016/j.bbrc.2016.12.186

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Agonist antibody discovery: Experimental, computational, and rational engineering approaches.

Authors:  John S Schardt; Harkamal S Jhajj; Ryen L O'Meara; Timon S Lwo; Matthew D Smith; Peter M Tessier
Journal:  Drug Discov Today       Date:  2021-09-24       Impact factor: 7.851

2.  A novel LRP1-binding peptide L57 that crosses the blood brain barrier.

Authors:  Kotaro Sakamoto; Tokuyuki Shinohara; Yusuke Adachi; Taiji Asami; Tetsuya Ohtaki
Journal:  Biochem Biophys Rep       Date:  2017-08-12

3.  Identification of ligand-selective peptidic ActRIIB-antagonists using phage display technology.

Authors:  Kotaro Sakamoto; Yoko Kanematsu-Yamaki; Yusuke Kamada; Masahiro Oka; Toshiyuki Ohnishi; Masanori Miwa; Taiji Asami; Hiroshi Inooka
Journal:  Biochem Biophys Rep       Date:  2017-06-10

4.  Single-chain tandem macrocyclic peptides as a scaffold for growth factor and cytokine mimetics.

Authors:  Kenichiro Ito; Yoshihiko Matsuda; Ayako Mine; Natsuki Shikida; Kazutoshi Takahashi; Kyohei Miyairi; Kazutaka Shimbo; Yoshimi Kikuchi; Atsushi Konishi
Journal:  Commun Biol       Date:  2022-01-14

Review 5.  T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target Specificity.

Authors:  Hui Yue; Yan Li; Mingying Yang; Chuanbin Mao
Journal:  Adv Sci (Weinh)       Date:  2021-12-16       Impact factor: 16.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.